Sprint Bioscience: Sprint Bioscience enters a VADA licensing agreement
Research Note
2023-08-17
07:15
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.
EL
Ethel Luvall
Disclosures and disclaimers